background
banner

RANEXA 500 Price

Active Substance: Ranolazine.

344
UAD , based on 7541 reviews.
View Drug details

Overview

Welcome to Dwaey, specifically on RANEXA 500 Tablets/Prolonged Release page.
This medicine contains an important and useful components, as it consists of Ranolazine.
RANEXA 500 is available in the market in concentration 500mg/Tablet and in the form of Tablets/Prolonged Release.

MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA is the producer of RANEXA 500 and it is imported from LUXEMBOURG, The most popular alternatives of RANEXA 500 are listed downward .

Mode Of Action

Ranolazine exert its antianginal and anti-ischaemic effects through concentration-, voltage-, and frequency-dependent inhibition of the late Na current and other cardiac ion channels and transporters. It may decrease the magnitude of the late Na current resulting in a net reduction in intracellular Na concentrations, reversal of Ca overload, restoration of ventricular pump function, and prevention of ischaemia-induced arrhythmias. Its antianginal effects are not dependent upon reductions in heart rate or BP and QT interval prolongation effect is caused by inhibition of rapid delayed rectifier K current (IKr), which prolongs the ventricular action potential.

Indication

  • Chronic angina

Precaution

Heart rhythm problems (e.g., bradycardia, QT prolongation, ventricular tachycardia), liver problems, certain uncorrected mineral imbalances (low potassium/magnesium levels), severe kidney problems. Lactation: Unknown if excreted in breast milk; discontinue or do not nurse

Side Effects

  • >10% Dizziness (5-13%) 1-10% Nausea (4-9%)
  • Constipation (5-8%)
  • Headache (3-6%)
  • Syncope (3%) Frequency Not Defined Palpitations
  • Bradycardia
  • Peripheral edema
  • Prolonged QT interval
  • Abdominal pain
  • Dry mouth
  • Dyspepsia
  • Anorexia
  • Vomiting
  • Hematuria
  • Dyspnea
  • Tinnitus
  • Vertigo
  • Blurred vision
  • Vasovagal syncope
  • Confusional state
  • Hematuria
  • Hyperhidrosis

Contra indication

Taking strong inhibitors of CYP3A (e.g., ketoconazole, clarithromycin, nelfinavir) Taking inducers of CYP3A (e.g., phenobarbital, rifampicin)Significant hepatic impairment

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased plasma levels w/ moderate CYP3A4 inhibitors (e.g. diltiazem, fluconazole, erythromycin), P-glycoprotein inhibitors (e.g. verapamil, ciclosporin) and CYP2D6 inhibitors (e.g. paroxetine). May increase plasma digoxin concentrations. May increase risk of rhabdomyolysis w/ simvastatin. May increase plasma concentrations of atorvastatin, other statins (e.g. lovastatin) and CYP3A4 substrates w/ narrow therapeutic range (e.g. tacrolimus, sirolimus, everolimus). May increase plasma exposure of metformin. Increased risk of ventricular arrhythmias w/ other drugs that prolong QT interval (e.g. terfenadine, astemizole, mizolastine). Potentially Fatal: Increased plasma concentrations leading to increased adverse effects w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone). Decreased plasma concentration w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine). Increased risk of QT interval prolongation w/ class 1A (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.

Alternatives Price List

  • RANEXA 750UAD 344
  • RANEXA 500UAD 344
  • RANEXA 375UAD 344

Releated Products

banner

Report Price Error

Please feel welcome to contact Us with any price or medical error. Our doctors will receive any reports.